WO2002023190A3 - Methods and products related to low molecular weight heparin - Google Patents

Methods and products related to low molecular weight heparin Download PDF

Info

Publication number
WO2002023190A3
WO2002023190A3 PCT/US2001/028457 US0128457W WO0223190A3 WO 2002023190 A3 WO2002023190 A3 WO 2002023190A3 US 0128457 W US0128457 W US 0128457W WO 0223190 A3 WO0223190 A3 WO 0223190A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
molecular weight
low molecular
weight heparin
products related
Prior art date
Application number
PCT/US2001/028457
Other languages
French (fr)
Other versions
WO2002023190A2 (en
WO2002023190A8 (en
Inventor
Mallikarjum Sundaram
Ganesh Venkataraman
Zachary Shriver
Dongfang Liu
Yi Wei Qi
Ram Sasisekharan
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Priority to JP2002527786A priority Critical patent/JP4911865B2/en
Priority to DK01972994T priority patent/DK1319183T3/en
Priority to DE60138115T priority patent/DE60138115D1/en
Priority to EP01972994A priority patent/EP1319183B1/en
Priority to AU2001292618A priority patent/AU2001292618A1/en
Priority to CA2422059A priority patent/CA2422059C/en
Publication of WO2002023190A2 publication Critical patent/WO2002023190A2/en
Publication of WO2002023190A3 publication Critical patent/WO2002023190A3/en
Publication of WO2002023190A8 publication Critical patent/WO2002023190A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Abstract

The invention relates to methods and products for characterizing and using polysaccharides. Low molecular weight heparin products and methods of use are described. Methods for characterizing purity and activity of polysaccharide preparations including glycosaminoglycans such as heparin are also described.
PCT/US2001/028457 2000-09-12 2001-09-12 Methods and products related to low molecular weight heparin WO2002023190A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002527786A JP4911865B2 (en) 2000-09-12 2001-09-12 Methods and products related to low molecular weight heparin
DK01972994T DK1319183T3 (en) 2000-09-12 2001-09-12 Methods and products related to low molecular weight heparin
DE60138115T DE60138115D1 (en) 2000-09-12 2001-09-12 METHOD AND PRODUCTS ASSOCIATED WITH LOW-MOLECULAR HEPARINE
EP01972994A EP1319183B1 (en) 2000-09-12 2001-09-12 Methods and products related to low molecular weight heparin
AU2001292618A AU2001292618A1 (en) 2000-09-12 2001-09-12 Methods and products related to low molecular weight heparin
CA2422059A CA2422059C (en) 2000-09-12 2001-09-12 Methods and products related to low molecular weight heparin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23199400P 2000-09-12 2000-09-12
US60/231,994 2000-09-12

Publications (3)

Publication Number Publication Date
WO2002023190A2 WO2002023190A2 (en) 2002-03-21
WO2002023190A3 true WO2002023190A3 (en) 2003-03-13
WO2002023190A8 WO2002023190A8 (en) 2011-10-27

Family

ID=22871450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/028457 WO2002023190A2 (en) 2000-09-12 2001-09-12 Methods and products related to low molecular weight heparin

Country Status (12)

Country Link
US (6) US7083937B2 (en)
EP (2) EP1319183B1 (en)
JP (2) JP4911865B2 (en)
AT (1) ATE426805T1 (en)
AU (1) AU2001292618A1 (en)
CA (1) CA2422059C (en)
CY (1) CY1110323T1 (en)
DE (1) DE60138115D1 (en)
DK (1) DK1319183T3 (en)
ES (2) ES2324701T3 (en)
PT (1) PT1319183E (en)
WO (1) WO2002023190A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012726A2 (en) 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US6597996B1 (en) * 1999-04-23 2003-07-22 Massachusetts Institute Of Technology Method for indentifying or characterizing properties of polymeric units
US6869789B2 (en) 2000-03-08 2005-03-22 Massachusetts Institute Of Technology Heparinase III and uses thereof
JP4911865B2 (en) 2000-09-12 2012-04-04 マサチューセッツ インスティテュート オブ テクノロジー Methods and products related to low molecular weight heparin
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
WO2003033512A2 (en) * 2001-10-16 2003-04-24 Procognia, Ltd. Method of preparing purified biologically active oligosaccharide libraries
AU2003225724A1 (en) 2002-03-11 2003-09-29 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
CA2483271A1 (en) * 2002-04-25 2003-11-06 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
CA2484604C (en) 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
EP1590648A4 (en) * 2002-05-20 2007-04-18 Massachusetts Inst Technology Novel method for sequence determination using nmr
AU2003243396A1 (en) 2002-06-03 2003-12-19 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
JP4606712B2 (en) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
DE10315581B4 (en) 2003-04-05 2007-06-28 Agilent Technologies, Inc. (n.d.Ges.d.Staates Delaware), Palo Alto Method for quality determination of RNA samples
WO2005054297A2 (en) 2003-11-28 2005-06-16 Eastman Chemical Company Cellulose interpolymers and method of oxidation
CA2558984A1 (en) 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) * 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060002594A1 (en) * 2004-06-09 2006-01-05 Clarke Allan J Method for producing a pharmaceutical product
US8101244B2 (en) 2004-06-09 2012-01-24 Smithkline Beecham Corporation Apparatus and method for producing or processing a product or sample
TWI547431B (en) 2004-06-09 2016-09-01 史密斯克萊美占公司 Apparatus and method for pharmaceutical production
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
DE102005038418A1 (en) * 2005-08-12 2007-02-15 Dade Behring Marburg Gmbh Factor Xa-based heparin assay using a heparin-modifying component
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
WO2007120478A2 (en) * 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
EP2447285A3 (en) 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
US7790466B1 (en) * 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
CN102802638B (en) * 2009-12-09 2015-11-25 新加坡科技研究局 glucosaminoglycan mixture
ES2817779T3 (en) * 2010-01-19 2021-04-08 Momenta Pharmaceuticals Inc Evaluation of heparin preparations
JP5645493B2 (en) * 2010-06-15 2014-12-24 川崎重工業株式会社 Polysaccharide inspection apparatus and polysaccharide inspection method
WO2012016216A2 (en) 2010-07-29 2012-02-02 Shire Human Genetic Therapies Assays for detection of glycosaminoglycans
AU2015203727B2 (en) * 2010-09-14 2016-05-26 Fuso Pharmaceutical Industries, Ltd. High Purity Heparin and Production Method Therefor
AU2011303081B2 (en) * 2010-09-14 2015-08-13 Fuso Pharmaceutical Industries, Ltd. High purity heparin and production method therefor
CN102792158B (en) * 2011-01-28 2013-07-10 杭州九源基因工程有限公司 Fine structure determination method of enoxaparin sodium based on capillary electrophoresis
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
BR112014014454B1 (en) * 2011-12-19 2021-03-09 Dilafor Ab non-anticoagulant glycosaminoglycans comprising repeated disaccharide unit and its medical uses
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
WO2013116677A2 (en) * 2012-02-01 2013-08-08 Shire Human Genetic Therapies, Inc. Assays for detection of glycosaminoglycans
ES2445494B1 (en) * 2012-08-02 2015-03-06 Rovi Lab Farmaceut Sa Procedure for obtaining low and very low molecular weight heparins
EP3997238A1 (en) 2019-07-09 2022-05-18 Optimvia, LLC Methods for synthesizing anticoagulant polysaccharides
CN111019014A (en) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 Preparation process of nadroparin calcium
EP4182452A1 (en) 2020-07-14 2023-05-24 Optimvia, LLC Methods for synthesizing non-anticoagulant heparan sulfate
CN114264741B (en) * 2021-12-15 2022-08-19 山东大学 Method for identifying whether pig-derived heparin is doped with ruminant heparin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569366A (en) * 1995-01-27 1996-10-29 Beckman Instruments, Inc. Fluorescent labelled carbohydrates and their analysis

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1390633A (en) * 1921-06-17 1921-09-13 Edgar A Milhaupt Bumper-bracket
US4281108A (en) 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
US4443545A (en) 1980-08-25 1984-04-17 Massachusetts Institute Of Technology Process for producing heparinase
US4341869A (en) 1980-08-25 1982-07-27 Massachusetts Institute Of Technology Process for producing heparinase
US4373023A (en) 1980-10-14 1983-02-08 Massachusetts Institute Of Technology Process for neutralizing heparin
US4396762A (en) 1981-08-24 1983-08-02 Massachusetts Institute Of Technology Heparinase derived anticoagulants
US4551296A (en) 1982-03-19 1985-11-05 Allied Corporation Producing high tenacity, high modulus crystalline article such as fiber or film
FR2554348B1 (en) 1983-11-04 1987-01-23 Tissier Gerard HEPARINIC COMPLEXES MARKED WITH SHORT LIFE RADIO ELEMENTS EMITTING NON-IONIZING RADIATIONS, PROCESS FOR OBTAINING THEM, INTERMEDIATE PRODUCTS AND APPLICATION OF SUCH COMPLEXES
US4757056A (en) 1984-03-05 1988-07-12 Hepar Industries, Inc. Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions
US4679555A (en) 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
FR2584728B1 (en) * 1985-07-12 1987-11-20 Choay Sa PROCESS FOR THE SULFATION OF GLYCOSAMINOGLYCANS AND THEIR FRAGMENTS
US5262403A (en) 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US5106734A (en) 1986-04-30 1992-04-21 Novo Nordisk A/S Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin
DK196986D0 (en) 1986-04-30 1986-04-30 Novo Industri As PREPARATION OF POLYSACCHARIDES
US4745105A (en) 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US4942156A (en) 1986-08-20 1990-07-17 Hepar Industries, Inc. Low molecular weight heparin derivatives having improved anti-Xa specificity
US4830013A (en) 1987-01-30 1989-05-16 Minnesota Mining And Manufacturing Co. Intravascular blood parameter measurement system
FR2614026B1 (en) 1987-04-16 1992-04-17 Sanofi Sa LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
SE8702254D0 (en) 1987-05-29 1987-05-29 Kabivitrum Ab NOVEL HEPARIN DERIVATIVES
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
US5169772A (en) 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
IT1234508B (en) 1988-06-10 1992-05-19 Alfa Wassermann Spa HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
GB8826448D0 (en) 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
IT1234826B (en) * 1989-01-30 1992-05-29 Alfa Wassermann Spa HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION
PT93847A (en) 1989-04-24 1990-11-20 Harvard College PROCESS FOR THE PREPARATION OF OLIGOSACARIDES OF LOW MOLECULAR WEIGHT DERIVED FROM HEPARIN OR DESPOLYMENED HEPARAN SULFATE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CA1340966C (en) 1989-05-19 2000-04-18 Thomas R. Covey Method of protein analysis
IT1237518B (en) 1989-11-24 1993-06-08 Renato Conti SUPER-SULFATED HEPARINS
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5152784A (en) 1989-12-14 1992-10-06 Regents Of The University Of Minnesota Prosthetic devices coated with a polypeptide with type IV collagen activity
US5284558A (en) 1990-07-27 1994-02-08 University Of Iowa Research Foundation Electrophoresis-based sequencing of oligosaccharides
IT1245761B (en) 1991-01-30 1994-10-14 Alfa Wassermann Spa PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLICANS ABSORBABLE ORALLY.
JP3110064B2 (en) 1991-03-06 2000-11-20 生化学工業株式会社 Novel heparitinase, method for producing the same and bacteria producing the same
US5262325A (en) 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
SK120193A3 (en) 1991-05-02 1994-07-06 Yeda Res & Dev Pharmaceutical composition for the prevention and/or treatment of pathological processes
WO1993005167A1 (en) 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
AU3144993A (en) 1991-11-21 1993-06-15 Glyko, Inc. Fluorophore-assisted therapeutic drug monitoring
GB9202019D0 (en) 1992-01-30 1992-03-18 Imperial College Methods and apparatus for assay of sulphated polysaccharides
IT1254216B (en) 1992-02-25 1995-09-14 Opocrin Spa POLYSACCHARIDIC DERIVATIVES OF HEPARIN, EPARAN SULPHATE, THEIR FRACTIONS AND FRAGMENTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5453171A (en) 1992-03-10 1995-09-26 The Board Of Regents Of The University Of Michigan Heparin-selective polymeric membrane electrode
US5856928A (en) 1992-03-13 1999-01-05 Yan; Johnson F. Gene and protein representation, characterization and interpretation process
GB9206291D0 (en) 1992-03-23 1992-05-06 Cancer Res Campaign Tech Oligosaccharides having growth factor binding affinity
WO1993019734A1 (en) 1992-04-02 1993-10-14 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
GB9306255D0 (en) 1993-03-25 1993-05-19 Cancer Res Campaign Tech Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity
FR2704861B1 (en) 1993-05-07 1995-07-28 Sanofi Elf Purified heparin fractions, process for obtaining them and pharmaceutical compositions containing them.
US7005510B1 (en) * 1993-06-23 2006-02-28 Beckman Instruments, Inc. Recombinant DNase B derived from Streptococcus pyogenes
WO1995013830A1 (en) 1993-11-17 1995-05-26 Massachusetts Institute Of Technology Method for inhibiting angiogenesis using heparinase
US6013628A (en) 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US6376196B1 (en) * 1996-05-10 2002-04-23 The Regents Of The University Of California Recombinant neospora antigens and their uses
US5607859A (en) 1994-03-28 1997-03-04 Massachusetts Institute Of Technology Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
WO1995030424A1 (en) 1994-05-06 1995-11-16 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
US5681733A (en) 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
US5619421A (en) 1994-06-17 1997-04-08 Massachusetts Institute Of Technology Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723847A1 (en) 1994-08-29 1996-03-01 Debiopharm Sa HEPARIN - BASED ANTITHROMBOTIC AND NON - HEMORRHAGIC COMPOSITIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS.
US5687090A (en) 1994-09-01 1997-11-11 Aspen Technology, Inc. Polymer component characterization method and process simulation apparatus
AU700903B2 (en) 1994-10-12 1999-01-14 Focal, Inc. Targeted delivery via biodegradable polymers
US5618917A (en) 1995-02-15 1997-04-08 Arch Development Corporation Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
US5763427A (en) 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
JP3318578B2 (en) 1995-05-26 2002-08-26 サーモディックス，インコーポレイティド Methods for promoting endothelialization and implantable products
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US5690910A (en) 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
WO1997016556A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5752019A (en) 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
CZ343798A3 (en) 1996-04-29 1999-02-17 Dura Pharmaceuticals, Inc. Inhaling system for inhaling dry powder
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
AU3892297A (en) 1996-07-26 1998-02-20 Ikonos Corporation Sensor for detecting heparin and other analytes
JP2000516708A (en) * 1996-08-08 2000-12-12 ウィリアム・マーシュ・ライス・ユニバーシティ Macroscopically operable nanoscale devices fabricated from nanotube assemblies
US5759767A (en) 1996-10-11 1998-06-02 Joseph R. Lakowicz Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids
ES2236832T3 (en) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology PREPARATION OF PARTICLES FOR INHALATION.
US6190875B1 (en) * 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6268146B1 (en) 1998-03-13 2001-07-31 Promega Corporation Analytical methods and materials for nucleic acid detection
WO2000012726A2 (en) 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
US6291439B1 (en) * 1998-09-02 2001-09-18 Biomarin Pharmaceuticals Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
US6597996B1 (en) 1999-04-23 2003-07-22 Massachusetts Institute Of Technology Method for indentifying or characterizing properties of polymeric units
US6869789B2 (en) 2000-03-08 2005-03-22 Massachusetts Institute Of Technology Heparinase III and uses thereof
IL151170A0 (en) * 2000-03-14 2003-04-10 Es Cell Int Pte Ltd Embryonic stem cells and neural progenitor cells derived therefrom
US6373194B1 (en) * 2000-06-01 2002-04-16 Raytheon Company Optical magnetron for high efficiency production of optical radiation
JP4911865B2 (en) 2000-09-12 2012-04-04 マサチューセッツ インスティテュート オブ テクノロジー Methods and products related to low molecular weight heparin
WO2002032406A2 (en) 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US6777244B2 (en) * 2000-12-06 2004-08-17 Hrl Laboratories, Llc Compact sensor using microcavity structures
US20020071457A1 (en) * 2000-12-08 2002-06-13 Hogan Josh N. Pulsed non-linear resonant cavity
CA2441986A1 (en) 2001-03-27 2002-10-03 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
US6788847B2 (en) * 2001-04-05 2004-09-07 Luxtera, Inc. Photonic input/output port
US7248297B2 (en) * 2001-11-30 2007-07-24 The Board Of Trustees Of The Leland Stanford Junior University Integrated color pixel (ICP)
EP1471828A1 (en) * 2002-01-18 2004-11-03 California Institute Of Technology Method and apparatus for nanomagnetic manipulation and sensing
CA2484604C (en) 2002-05-03 2011-08-02 Massachusetts Institute Of Technology .delta. 4,5 glycuronidase and uses thereof
EP1590648A4 (en) 2002-05-20 2007-04-18 Massachusetts Inst Technology Novel method for sequence determination using nmr
AU2003243396A1 (en) 2002-06-03 2003-12-19 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
US6887773B2 (en) * 2002-06-19 2005-05-03 Luxtera, Inc. Methods of incorporating germanium within CMOS process
AU2003296909A1 (en) * 2002-09-27 2004-05-13 The Trustees Of Dartmouth College Free electron laser, and associated components and methods
US6922118B2 (en) * 2002-11-01 2005-07-26 Hrl Laboratories, Llc Micro electrical mechanical system (MEMS) tuning using focused ion beams
JP4606712B2 (en) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2-O sulfatase compositions and related methods
US7141800B2 (en) * 2003-07-11 2006-11-28 Charles E. Bryson, III Non-dispersive charged particle energy analyzer
US20050186679A1 (en) * 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
US7851223B2 (en) 2004-02-27 2010-12-14 Roar Holding Llc Method to detect emphysema
CA2558984A1 (en) 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
EP1582531A1 (en) * 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
US20060057638A1 (en) 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US7586097B2 (en) * 2006-01-05 2009-09-08 Virgin Islands Microsystems, Inc. Switching micro-resonant structures using at least one director
US20060154894A1 (en) 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
US20060187794A1 (en) * 2004-10-14 2006-08-24 Tim Harvey Uses of wave guided miniature holographic system
EP1841449A2 (en) 2005-01-12 2007-10-10 The Massachusetts Institute Of Technology Methods and compositions related to modulating the extracellular stem cell environment
US20090155875A1 (en) 2005-02-16 2009-06-18 Massachusetts Institute Of Technology Methods to Enhance Carbon Monoxide Dehydrogenase Activity and Uses Thereof
US20090105463A1 (en) 2005-03-29 2009-04-23 Massachusetts Institute Of Technology Compositions of and Methods of Using Oversulfated Glycosaminoglycans
WO2006105315A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions and methods for regulating inflammatory responses
US7619373B2 (en) * 2006-01-05 2009-11-17 Virgin Islands Microsystems, Inc. Selectable frequency light emitter
WO2007120478A2 (en) 2006-04-03 2007-10-25 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569366A (en) * 1995-01-27 1996-10-29 Beckman Instruments, Inc. Fluorescent labelled carbohydrates and their analysis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KISHIBE ET AL: "Structural requirements of heparan sulfate for the binding to the tumor-derived adhesion factor/angiomodulin that induces cord-like structures to EVC-304 human carcinoma cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 20, 19 May 2000 (2000-05-19), pages 15321 - 15329, XP002223526 *

Also Published As

Publication number Publication date
AU2001292618A1 (en) 2002-03-26
DE60138115D1 (en) 2009-05-07
EP2085780A3 (en) 2011-08-17
JP4911865B2 (en) 2012-04-04
JP2011169913A (en) 2011-09-01
US7687479B2 (en) 2010-03-30
US8173384B2 (en) 2012-05-08
US7399604B2 (en) 2008-07-15
US20060024664A1 (en) 2006-02-02
DK1319183T3 (en) 2009-05-18
CA2422059C (en) 2012-05-15
ES2324701T3 (en) 2009-08-13
JP5186019B2 (en) 2013-04-17
PT1319183E (en) 2009-06-29
EP1319183B1 (en) 2009-03-25
ATE426805T1 (en) 2009-04-15
CA2422059A1 (en) 2002-03-21
WO2002023190A2 (en) 2002-03-21
US20020169143A1 (en) 2002-11-14
JP2004509339A (en) 2004-03-25
EP1319183A2 (en) 2003-06-18
ES2640975T3 (en) 2017-11-07
US20100062468A1 (en) 2010-03-11
US20130017565A1 (en) 2013-01-17
US20070161073A1 (en) 2007-07-12
US7083937B2 (en) 2006-08-01
EP2085780B1 (en) 2017-06-21
US20070065921A1 (en) 2007-03-22
EP2085780A2 (en) 2009-08-05
US7585642B2 (en) 2009-09-08
US8512969B2 (en) 2013-08-20
WO2002023190A8 (en) 2011-10-27
CY1110323T1 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
WO2002023190A8 (en) Methods and products related to low molecular weight heparin
WO2001058412A3 (en) Extracts from residues left in the production of wine
AU2003251221A1 (en) Microbeads of natural polysaccharide and hyaluronic acid and processes for preparing the same
MXPA01007710A (en) Freeze-dried agent containing paramylon, production and utilization thereof.
AU2525401A (en) Use of an extract of at least one vaccinium-type plant as an anti-glycation agent
AU2764592A (en) Beta -1,3-glucan polysaccharides, compositions, and their preparation and uses
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
EP1880735A3 (en) Vaccine
AU2002246734A1 (en) Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
AU2003245252A8 (en) Enhanced sulfated polysaccharide formulations, methods and preparations and their uses thereof
WO2000046359A3 (en) Medicament
HUP0300755A2 (en) Heparin-derived polysaccharide mixtures, preparation method and pharmaceutical compositions containing same
HK1080872A1 (en) Highly branched, unsubstituted or low-substituted starch products, dialysis solution and plasma expander containing the same, and the use thereof
WO1999040083A3 (en) Bifunctional tryptase inhibitors
WO2002030941A3 (en) Topoisomerase inhibitors
DE60006448D1 (en) Mercapto alcohol compounds than as flavorings
WO2003018059A3 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
AU2001246510A1 (en) Glycosaminoglycans derived from the k5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
WO2000014097A3 (en) Novel pyranoses
AU2002358215A1 (en) Improvements in or relating to liquid, eye-instillable preparations comprising sodium hyaluronate
CA2263846A1 (en) Novel pyranoside derivatives
SE9803107D0 (en) Novel Compunds
WO2002057281A3 (en) Aminoglycosides as antibiotics
WO2001040241A3 (en) 6-o-alkyl-2-nor-2-substituted ketolide derivatives
WO2001060801A3 (en) 9-alkylamino-1-nitroacridine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001292618

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2422059

Country of ref document: CA

Ref document number: 2002527786

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001972994

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001972994

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)